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Background: This randomized, open-label study was conducted to establish the non-inferiority of a combination of
azithromycin (AZ) and chloroquine (CQ) to artemether-lumefantrine (AL) for treatment of uncomplicated malaria in
children from six sites in sub-Saharan Africa.
Methods: Children with uncomplicated Plasmodium falciparum malaria between six and 59 months of age were
randomized 1:1 to either AZCQ (30 mg/kg AZ + 10 mg/kg CQ base) or AL per prescribing information for three
days (Days 0, 1, 2). Each site could enrol in the study population once the treatment of uncomplicated malaria in
five children five to 12 years of age was deemed to be effective and well tolerated. The primary efficacy evaluation
was the proportion of subjects in both the modified intent-to-treat (MITT) and per-protocol (PP) populations with
an adequate clinical and parasitological response (PCR corrected) at Day 28. Non-inferiority was concluded if the
lower bound of the 95% confidence interval comparing the two groups was 10 percentage points or greater.
Results: A total of 255 children were enrolled in the efficacy analysis (AZCQ, n = 124; AL, n = 131). The PCR corrected
clearance rates were 89% (AZCQ) versus 98% (AL) for MITT, a difference of -9.10 (95% confidence interval; -16.02, -2.18)
and 93% (AZCQ) versus 99% (AL) for PP, a difference of -6.08 (-12.10, -0.05). Early and late treatment failures were more
common in subjects receiving AZCQ. Adverse events were more common in subjects treated with AZCQ. Drug
concentrations obtained at specified time points following AZCQ administration had a large coefficient of variation
partially due to sparse sampling with sample collection time window.
Conclusions: In this study, non-inferiority of AZCQ to AL was not demonstrated.
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Malaria, a disease caused by five different species of Plas-
modium, continues to be a global health problem [1].
Throughout the world, approximately 207 million cases of
malaria were reported in 2012, 80% in Africa. Plasmodium
falciparum accounted for 91% of total cases. The vast ma-
jority of the estimated 627,000 malaria deaths occurred in
2012, 90% in Africa, and children under five years
accounted for 77% of these deaths [1]. The World Health
Organization (WHO) recommends an artemisinin-based
combination therapy (ACT) for uncomplicated malaria
caused by P. falciparum [2].
The combination of azithromycin (AZ) and chloro-
quine (CQ) has been shown to have synergistic activity
in vitro and in vivo against CQ-resistant strains of P. fal-
ciparum [3-5]. AZ and CQ are marketed drugs, and
there is extensive experience with each of these agents
in the paediatric population. The efficacy and safety of a
fixed-dose combination of AZ and CQ (AZCQ) for the
treatment of symptomatic, uncomplicated P. falciparum
malaria in adults were recently demonstrated in two
multicentre phase 3 clinical studies in Africa [6,7] and in
phase 2 studies in India and Colombia [8-10]. In a separ-
ate study, a fixed-dose combination of AZCQ is currently
undergoing evaluation for intermittent preventative treat-
ment in pregnancy (IPTp) [11]. The objective of this study
(ClinicalTrials.gov identifier NCT00677833) was to estab-
lish the non-inferiority of AZCQ compared with the ACT
combination artemether-lumefantrine (AL) for treatment




This was an open-label, randomized, phase 2/3 study at
six sites (two centres in Burkina Faso and one centre
each in Kenya, Ghana, Mali, and Ivory Coast) in sub-
Saharan Africa that compared the efficacy (adequate
clinical and parasitological response (ACPR)) of AZCQ
with that of AL in treatment of children with symptom-
atic uncomplicated falciparum malaria. An independent
external data monitoring committee (EDMC), compris-
ing international and regional malaria researchers, had
oversight of the study. The study was conducted be-
tween June 2008 and September 2010.
Subjects
To be eligible for participation in the study, subjects
were required to be able to receive treatment on an out-
patient basis. Subjects were included if age ranged from
five to 12 years of age (screening cohort) or between six
and 59 months of age (primary study cohort) and had un-
complicated, symptomatic malaria. The presence of mal-
aria was defined as positive blood smears for P. falciparum,mono-infection with parasite counts between 1,000 to
100,000 parasites/μL, and documented fever (≥38.0°C,
rectal or tympanic; or ≥37.2°C axillary or ≥37.5°C oral),
or history of fever within the previous 24 hours. Sub-
jects also had to have a blood glucose ≥60 mg/dL and
haemoglobin ≥6 g/dL or haematocrit ≥18% without
signs of anaemia-induced congestive heart failure, and a
negative urine pregnancy test for females ≥ ten years of
age. Informed consent for the study and permission
from subjects’ legal guardian for the three-day inpatient
stay was also needed. Concomitant use of medications
(e.g., anti-emetics, antipyretics) was permitted. Use of
medications with known drug interactions with macro-
lides was closely monitored. Medications metabolized
by the CYP2D6 isoenzyme were not permitted (contra-
indicated with AL). In addition, agents that prolong the
QT interval and concomitant administration of other
anti-malarial drugs were avoided because of limited
safety data with AL.
Exclusion criteria included subjects with severe or com-
plicated malaria or a peripheral blood smear indicating a
mix of Plasmodium species, any history of allergy/hyper-
sensitivity to or contraindication for use of any of the study
drugs or history of treatment with anti-malarial drugs
within two weeks prior to enrollment, body weight <5 kg
or severe malnutrition, and known or suspected cardiovas-
cular, hepatic, or renal abnormality, specific systemic dis-
eases, or other medical conditions that would interfere
with the evaluation of therapeutic response or safety of the
study drug, other severe acute or chronic medical or psy-
chiatric condition or laboratory abnormality, or other com-
mon febrile conditions, such as tonsillitis, measles, etc.
Study procedure
In Burkina Faso, the National Ethical Committee for
Health Research reviewed and approved the final proto-
col, informed consent, and any amendments. At all other
study centres, this review and approval was done by the
institutional review board at each study centre. Over-
sight of safety data evaluation was provided through the
activities of the EDMC. This study was conducted in
compliance with the ethical principles originating in or
derived from the Declaration of Helsinki and in compli-
ance with all International Conference on Harmonization
Good Clinical Practice Guidelines. The study protocol was
submitted to the US Food and Drug Administration under
an Investigational New Drug application. All local regula-
tory requirements were also followed.
Subject enrolment was carried out in two stages. Each
site was required to initially enrol ten evaluable subjects
in a screening cohort (Cohort 1) of older children (five
to 12 years of age) who were assumed to have some de-
gree of immunity to P. falciparum before proceeding
with the primary study population cohort (Cohort 2) of
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to proceed to Cohort 2 for each site was based on the
safety and efficacy of five evaluable AZCQ subjects ob-
served in Cohort 1 at that site. The site could begin en-
rolling in Cohort 2 if all five evaluable subjects in the
AZCQ group of Cohort 1 demonstrated a clinical and
parasitological response within the first seven days of
treatment initiation, continued clearance of parasitaemia
through Day 28, and no clinically significant safety and
tolerability issues were noted. If four of five subjects in
the AZCQ arm demonstrated parasitological clearance
and a clinical response within the first seven days of treat-
ment initiation, the centre continued to enrol approxi-
mately ten additional subjects with five evaluable subjects
receiving AZCQ. Continuing onto Cohort 2 required that
eight or more of ten AZCQ-treated subjects demonstrated
a clinical response and parasitologic clearance up to Day
28, and no significant safety and tolerability issues were
noted. If fewer than four of five subjects in the AZCQ arm
met the above criteria, the EDMC evaluated data from all
sites and made recommendations on when to proceed
with Cohort 2 enrolment. In all other cases, the decision
to move from Cohort 1 to Cohort 2 for each centre was
made by the investigator, the sponsor (Pfizer), and occa-
sionally the EDMC.
In each cohort, subjects were randomized 1:1 to either
receive an AZCQ fixed-dose combination tablet (30 mg/
kg AZ + 10 mg /kg CQ base) orally once daily for three
days (Days 0, 1, 2) or AL orally per prescribing informa-
tion for three days (Days 0, 1, 2). A computer-generated
randomization list was provided to investigators and
randomization numbers were assigned sequentially as
subjects were deemed eligible to participate in the study.
Random assignment to either the AZCQ or AL treat-
ment groups was determined by the assigned number
from the randomization list. Two strengths of AZCQ
were available for this study: AZ 300 mg/CQ 100 mg
and AZ 150 mg/CQ 50 mg. Tablets were scored to allow
for dosing by body weight. Subjects received AZCQ 300/
100-mg tablets for ≥20 kg body weight: and AZCQ 150/
50-mg tablets for 5 to <20 kg body weight. When pos-
sible, the study drugs were administered with or imme-
diately after food consumption. Any dose of AZCQ that
was vomited within 30 minutes of administration and
any dose of AL that was vomited within 60 minutes of
administration was repeated once. If vomiting recurred,
the subject was discontinued from the study treatment.
At enrolment, the presence of P. falciparum was iden-
tified using a blood dipstick-based test (Binax NOW
immunochromatographic test (ICT)) and confirmed by
microscopy on a Giemsa-stained peripheral blood smear.
All eligible subjects were then hospitalized for ≥ three
days for study drug administration and monitoring of the
study key parameters. During this time, blood smears(thick and thin) were obtained every eight hours until two
consecutive smears showed absence of parasitaemia. Clin-
ical assessments, including adverse events (AEs), thick and
thin peripheral smears and vital signs were evaluated on
study Days 0, 3, 7, 14, 21, 28, 35, and 42. Electrocardio-
grams were performed in a limited number of subjects on
study Days 0 and 2. At each site, clinical presentation and
smear results from each study day were used to determine
subject management. Discharge from the hospital oc-
curred following clearance of asexual parasitaemia and
investigator approval. All subjects were given insecticide-
treated bed nets for use in the hospital and for use at
home once discharged.
Sparse pharmacokinetic (PK) blood samples were col-
lected only in the AZCQ treatment group to determine
serum AZ, plasma CQ, and desethyl-CQ concentrations.
Whole blood samples were collected on Day 0 (prior to
the first dose) at 0 hours (window: -1 to 0 hour); on Day
2 (the day of the third dose) at 0 (pre-dose, window: -1
to 0 hr), three (window: 2–4 hours), and eight hours
(window: 6–10 hours), and randomly on Day 7. Samples
were either centrifuged at 3,500 rpm for 10 min at 4°C
or the centrifuge bucket and rotor were chilled on ice or
in a refrigerator for two hours prior to use. Samples
were stored within one hour of collection at -20°C until
shipped for assay. AZ, CQ and desethyl-CQ concentra-
tions were analysed using validated, sensitive and specific
high-performance liquid chromatography tandem mass
spectrometric methods in compliance with Pfizer standard
operating procedures. AZ assays were performed by Bioa-
nalytical Systems, Ltd (BASi) (Warwickshire, UK) and
CQ/desethyl-CQ assays were performed by Cetero Re-
search (Houston, TX, USA) [12].
A prospectively planned interim analysis was con-
ducted to evaluate safety and efficacy endpoints when
approximately 50% of the subjects enrolled in Cohort 2
(approximately 52 evaluable subjects per arm) completed
the Day 28 visit. Interim data were reviewed by the
EDMC, and a determination to continue the study was
made based on a predefined futility criterion (ACPR).
ACPR was defined as asexual P. falciparum parasitologic
clearance at Day 28 irrespective of axillary, oral, rectal, or
tympanic temperature without previously meeting the cri-
teria of early treatment failure or polymerase chain reac-
tion (PCR)-corrected late treatment failure. PCR-corrected
refers to the use of molecular testing to differentiate re-
crudescence from re-infection when evaluating efficacy
(see Table 1 for full definitions). Filter-paper samples were
used for molecular analyses and gene amplification of
merozoite surface proteins (MSP-1, MSP-2), Ca1, TA-87,
and TA-99 polymorphisms to distinguish recrudescence
from new infections [13-16]. A subject was classified as a
true failure if the sample was recrudescent with all five
genotypic markers (i.e., all five markers matched those
Table 1 Treatment failure definitions [17]
Early treatment
failure (ETF)
● Signs of severe malaria/clinical deterioration
requiring rescue medication on Days 0, 1, 2
or 3, in the presence of P. falciparum
parasitaemia*
● Last available asexual P. falciparum parasite
count on Day 2 greater than the first available
parasite count at baseline irrespective of
axillary, oral, or rectal temperature
● Parasitaemia (P. falciparum) on Day 3 with
fever†
● Last available P. falciparum parasite count
on Day 3≥ 25% of the first available parasite
count at baseline
Late treatment failure
Late clinical failure (LCF) ● Signs of severe malaria/ clinical deterioration
requiring rescue medication after Day 3 in
the presence of P. falciparum parasitaemia,
without previously meeting any of the
criteria of ETF
● Presence of P. falciparum parasitaemia and
fever† on any day from Day 4 onward,




● Presence of P. falciparum parasitaemia on
any day from Day 7 onward and the
absence of fever without previously
meeting any of the criteria of ETF or LCF
*For treatment failure, any subject with a missing blood smear was assumed
to have parasitaemia.
†Fever was defined as ≥38.0°C (rectal), ≥37.2°C (axillary), or ≥37.5°C (oral).
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mixed infection that contained parasites genotypically
identical to those from Day 0 were counted as recrudes-
cent. Change of profile in any or all loci was counted as
re-infection. Although the study was open-label, the study
team was blinded to the emerging cumulative data
reviewed by the independent external EDMC.
Laboratory assessment
Peripheral blood smear examinations were conducted to
evaluate eligibility for inclusion by assessing parasite
counts and identifying parasite species, parasite suscepti-
bility to CQ and response to treatment. Molecular testing
was done to genotype the P. falciparum parasites at base-
line and when parasitaemia occurred after initial clear-
ance. Recurrence (reappearance of asexual P. falciparum
parasitaemia following a quiescent or latent period after
cessation of the primary attack) was categorized as either
recrudescence (reappearance of asexual P. falciparum
blood stage parasites of same genotype confirmed by mo-
lecular testing), or re-infection (infection by a different
genotypic parasite as documented by molecular testing).
Statistical analysis
Cohort 1 and Cohort 2 were analysed independently. Be-
cause Cohort 1 was only a small screening cohort, althoughdata were analysed, no formal statistical inference was
made. Three study populations were defined: 1) all treated
subjects (for safety analyses); 2) modified intent-to-treat
(MITT), defined as a subset of subjects in the all-treated
subjects population who met the specified disease criteria
at baseline; and, 3) the per-protocol (PP) population, de-
fined as a subset of subjects in the MITT population who
received all three days of assigned study medication.
External quality checks were conducted for on-site mi-
croscopists. At Ivory Coast, all three microscopists failed
the parasite-count evaluation; therefore, data (nine sub-
jects) from Ivory Coast were excluded from all ACPR
analyses for both the MITT and PP populations, but in-
cluded in sensitivity analysis for the MITT population.
The primary efficacy endpoint was the proportion of
subjects with PCR-corrected ACPR at the Day 28 evalu-
ation. Two datasets were analysed for efficacy: the MITT
and PP populations (excluding data from Ivory Coast).
Cohort 2 was the focus of the efficacy analysis. The pri-
mary analysis variable was the time (days) to the first oc-
currence of treatment failure analysed using the Kaplan-
Meier method (see Table 1 for categorization of treatment
failure events). Subjects without a treatment failure event
during the study were censored using the Kaplan-Meier
method as listed below.
 Subjects who withdrew from the study due to any
reason other than treatment failure were censored
on the day of the last available blood smear
measurement.
 Subjects who received an anti-malarial concomitant
medication for treatment of a reinfection (in a PCR-
corrected analysis) were censored at the visit date if
the anti-malarial was given after collection of the
blood smear on that day. Otherwise, the subject was
censored on the day of the last available blood smear
measurement taken prior to the visit. Note that in a
PCR-uncorrected analysis, this type of censoring
only occurred when a subject was treated at a visit
based on symptoms but later found not to have
parasitaemia.
The proportion of subjects with ACPR at each planned
visit (i.e., Days 7, 14, 21, 28 (primary), 35, 42) was esti-
mated from the Kaplan-Meier curve. A two-sided 95%
confidence interval (CI) for the difference in ACPR pro-
portions (AZCQ – AL) was constructed. Non-inferiority
was concluded if the lower boundary of the CI was greater
than or equal to -10 percentage points for both the MITT
and PP populations at Day 28 (PCR-corrected).
A sensitivity analysis was conducted to support the
primary efficacy analysis for both the MITT and PP pop-
ulations. This sensitivity analysis considered subjects
who prematurely discontinued from the study due to
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ures at the time of withdrawal.
Secondary study endpoints included ACPR (PCR-cor-
rected and -uncorrected) at Days 7, 14, 21, 28 (uncor-
rected), 35, and 42 as well as early and late treatment
failures (Table 1), time to fever clearance, and gameto-
cyte clearance. The time to fever clearance was analysed
in a similar manner to ACPR, with Kaplan-Meier esti-
mates. Clearance was defined as the time (in days) from
the start of treatment administration to the first of the
two consecutive time points at which fever was no longer
present. Absence of gametocytes was defined as clearance
of P. falciparum gametocytaemia (i.e., attainment of two
consecutive zero gametocyte counts) without subsequent
recurrence through the day of consideration. With the ex-
ception of ACPR, all other secondary endpoints were ana-
lysed using the MITT study population. Descriptive
statistics of concentration data for serum AZ, plasma CQ
and plasma desethyl-CQ were provided by treatment, co-
hort, study day, and nominal time post-dose.
A target sample size of approximately 244 subjects in
Cohort 2 (approximately 122 subjects per arm) was deter-
mined based on the following assumptions: 1) an evalu-
ability rate (for the purpose of sample size determination)
of 85% corresponding to the Day 28 visit (this would re-
sult in 104 evaluable subjects in each treatment arm); 2)
an expected ACPR (PCR-corrected) rate of 95% in the
AZCQ group and 95% in the AL group; 3) a power of 80%
to show non-inferiority of the AZCQ group relative to the
AL group; and, 4) accounting for any loss in power due to
the efficacy futility interim analysis.
Results
Cohort 1
The screening cohort included 106 subjects. After exclud-
ing subjects from the Ivory Coast, the MITT population
included 85 subjects. Four subjects or their parent/legal
guardian in the AZCQ treatment group were no longer
willing to participate and discontinued from the study.
There were no treatment discontinuations in the AL
group. The mean age was 7.4 years for AZCQ-treated sub-
jects and 7.9 years for AL-treated subjects. The AL group
had a higher proportion of males. All subjects had con-
firmed P. falciparum malaria following blood smear mi-
croscopy with mean baseline parasite counts that ranged
from 1,000/μL to 110,240/μL. All study centres met the
criteria for enrolling subjects into Cohort 2.
Cohort 2
Subject disposition and demographics
The primary study population included 255 subjects who
were screened and randomized (Figure 1). After excluding
subjects from the Ivory Coast, the MITT population
included 246 subjects. One subject or their parent/legalguardian in the AZCQ group was no longer willing to par-
ticipate and discontinued from the study, and one subject
was lost to follow-up. Treatment discontinuation due to
AEs occurred in seven subjects in the AZCQ group. Three
subjects or their parent/legal guardian in the AL treatment
group were no longer willing to participate and discontin-
ued from the study, and one subject stopped treatment
because of AEs.
Demographic characteristics of treatment groups were
similar, except for gender ratio; there was a higher propor-
tion of males in the AZCQ group (Table 2). The mean age
was 2.4 years for the AZCQ group and 2.7 years for the
AL group.Baseline disease characteristics
At baseline, all subjects had either fever or a history of
fever within 24 hours of consent to participate in the
study. The mean duration between subjects’ first malaria
symptom and initiation of consent process for this study
was 1.9 days, and ≤ three hours elapsed between consent
and drug administration in all but 12 subjects.Efficacy results
Efficacy data were used to determine if AZCQ was non-
inferior to AL; based on the primary endpoint of ACPR
at Day 28 (PCR-corrected), non-inferiority of AZCQ to
AL was not demonstrated. In the MITT population, 89%
(95% CI: 83%, 96%) of subjects in the AZCQ group ver-
sus 98% (95% CI: 96%, 100%) in the AL group achieved
the primary endpoint (Table 3). The difference between
treatment groups in the MITT (AZCQ-AL) was -9%
(95% CI, -16%, -2%), which did not meet the pre-
specified non-inferiority criterion (lower bound of the
CI ≥ -10% was needed to conclude non-inferiority). Re-
sults for the PP population were similar to the MITT. In
the PP population, 93% (95% CI: 87%, 99%) in the
AZCQ group versus 99% (95% CI: 97%, 100%) in the AL
group achieved the primary endpoint (Table 3). The
between-group differences in the PP population (AZCQ-
AL) was -6% (95% CI, -12%, -0.1%), which also did not
meet the non-inferiority criterion. Although not a pre-
specified comparison in the study protocol, since the CI
for both the MITT and PP populations also excluded zero,
AZCQ was inferior to AL at the Day 28 time point.
The proportion of subjects with ACPR (PCR-corrected)
was numerically higher in the AL group than in the
AZCQ group at all visits for both analysis populations
(Table 3). A significant difference between groups was
noted at all visits except Day 35 in the MITT population.
The PCR-uncorrected results (Table 4) were markedly
lower than those that were PCR-corrected starting at Day
21 onward. In the MITT population, proportion of PCR-
uncorrected ACPR was 52% of subjects in the AZCQ
Figure 1 Subject disposition (Cohort 2). AE = adverse event, AL = artemether-lumefantrine, AZCQ = azithromycin-chloroquine fixed-dose
combination, MITT = modified intent-to-treat, PP = per protocol. *Includes 1 subject who discontinued treatment due to an AE.
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findings in the PP population.
Most (eight of 12 and one of two in the AZCQ and AL
groups, respectively) of the treatment failures (up to Day
28 including early treatment failures) were from a single
centre (Mali). Estimates of ACPR at Day 28 (MITT) were
essentially unchanged when accounting for each subject’s
baseline parasite count (i.e., treatment groups comparedTable 2 Demographic characteristics (Cohort 2)
AZCQ AL
N = 124 N = 131
Male (n, %) 74 (59.7) 66 (50.4)
6 months to <5 years (n, %) 123 (99.2) 129 (98.5)
5 years (n, %)* 1 (0.8) 2 (1.5)
Age (years) mean (SD) 2.4 (1.3) 2.7 (1.0)
Range 0.5-5.0 0.5-5.0
Weight (kg) mean (SD) 12.5 (3.1) 12.8 (2.5)
Range 6.1-19.0 6.9-18.0
Height (cm), mean (SD) 90.2 (11.6) 92.7 (9.5)
Range 59.0-115.0 66.3-116.0
Body mass index (kg/m2) mean (SD) 15.2 (1.6) 14.9 (1.6)
Range 9.5-20.7 8.4-20.3
AL = artemether-lumefantrine, AZCQ = azithromycin-chloroquine fixed-dose
combination, SD = standard deviation.
*Three subjects who were 5 years of age were protocol violations.within two subgroups based on whether a subject’s base-
line parasite count was above or below the median ob-
served value of 13,120). Early treatment failures were
more common in the AZCQ group (5.83% (MITT) and
1.75% (PP)) than in the AL group (0.79% (MITT) and 0%
(PP)). Also, higher proportions of late parasitological fail-
ures were observed in the AZCQ group (4.17% (MITT)
and 4.39% (PP)) than in the AL group (0.79% (MITT) and
0.81% (PP)). No late clinical failures were observed in
either treatment group (MITT or PP).
The time to fever clearance between groups was ap-
proximately 24 hours in both treatment groups with no
statistically significant difference between groups. One
subject in each treatment group had fever that persisted
for more than 72 hours despite being aparasitaemic from
study Day 1 (AL) or study Day 2 (AZCQ). Plasmodium
falciparum gametocyte clearance rates were higher at all
time points for AL-treated subjects (>90%) compared
with that for AZCQ-treated subjects (>80%).
Pharmacokinetic results
Serum concentrations of AZ and plasma concentrations
of CQ and desethyl-CQ in each cohort and for the com-
bination of cohorts are reported in Table 5. A large coef-
ficient of variation, ranging from 39 to 93%, was
observed in the concentration data and may have been
caused partially by the PK sampling time window and
approximate weight-based dose according to design.
Table 3 ACPR (PCR-corrected) at Days 7, 14, 21, 28, 35, 42 (Cohort 2)
Percentage of subjects
with ACPR* (95% CI)†
MITT population PP population
AZCQ N = 120 AL N = 126 AZCQ N = 114 AL N = 124
Day 7 94.17 (89.55, 98.78) 99.21 (97.25, 100.00) 98.25 (95.39, 100.00) 100.00 (−)
ACPR % difference‡, 95% CI† -5.04 (-9.93, -0.15) -1.75 (−)
Day 14 92.47 (87.30, 97.64) 99.21 (97.24, 100.00) 96.46 (92.59, 100.00) 100.00 (−)
ACPR % difference‡, 95% CI† -6.74 (-12.15, -1.32) -3.54 (−)
Day 21 91.59 (86.04, 97.14) 98.37 (95.65, 100.00) 95.53 (91.10, 99.96) 99.16 (97.03, 100.00)
ACPR % difference‡, 95% CI† -6.78 (-12.82, -0.75) -3.63 (-8.40, 1.14)
Day 28§ 89.27 (82.77, 95.77) 98.37 (95.59, 100.00) 93.08 (87.32, 98.84) 99.16 (96.97, 100.00)
ACPR % difference‡, 95% CI† -9.10 (-16.02, -2.18) -6.08 (-12.10, -0.05)
Day 35 89.27 (82.68, 95.86) 96.19 (91.85, 100.00) 93.08 (87.22, 98.95) 96.96 (92.90, 100.00)
ACPR % difference‡, 95% CI† -6.92 (-14.59, 0.76) -3.87 (-10.79, 3.04)
Day 42 87.55 (80.08, 95.03) 96.19 (91.79, 100.00) 91.29 (84.31, 98.28) 96.96 (92.84, 100.00)
ACPR % difference‡, 95% CI† -8.63 (-17.08, -0.18) -5.66 (-13.55, 2.22)
ACPR = adequate clinical and parasitologic response, AL = artemether-lumefantrine, AZCQ = azithromycin-chloroquine fixed-dose combination, CI = confidence
interval, MITT =modified intention-to-treat, PP = per protocol.
*Estimated from Kaplan-Meier curve.
†CI by large sample approximation to the binomial with continuity correction using the standard error estimated by the Greenwood formula.
‡Difference calculated from rates estimated from the Kaplan-Meier curves.
§Primary endpoint.
Note: Group-specific confidence intervals and the confidence interval for the difference between treatment groups were not calculated when all failures occurred
in a single group.
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The safety population included 361 subjects randomized
in this study. No deaths occurred during the study. Four
serious AEs (SAEs) were reported. Three SAEs occurred
in Cohort 1 (malaria (AZCQ group), sepsis and hepatitisTable 4 ACPR (PCR-uncorrected) at Days 7, 14, 21, 28, 35, 42
Percentage of subjects
with ACPR* (95% CI)†
MITT population
AZCQ N = 120 AL N = 1
Day 7 94.17 (89.55, 98.78) 99.21 (9
ACPR % difference‡, 95% CI† -5.04 (-9.93, -0.15)
Day 14 89.08 (83.05, 95.11) 96.79 (9
ACPR % difference‡, 95% CI† -7.71 (-14.54, -0.88)
Day 21 67.87 (59.02, 76.72) 82.96 (7
ACPR % difference‡, 95% CI† -15.09 (-26.24, -3.94)
Day 28 51.55 (42.07, 61.02) 73.31 (6
ACPR % difference‡, 95% CI† -21.79 (-34.14, -9.39)
Day 35 44.67 (35.24, 54.11) 62.91 (5
ACPR % difference‡, 95% CI† -18.24 (-31.05, -5.43)
Day 42 37.80 (28.58, 47.02) 56.29 (4
ACPR % difference‡, 95% CI† -18.49 (-31.33, -5.65)
ACPR = adequate clinical and parasitologic response, AL = artemether-lumefantrine,
interval, MITT =modified intention-to-treat, PP = per-protocol.
*Estimated from Kaplan-Meier curve.
†CI by large sample approximation to the binomial with continuity correction using
‡Difference calculated from rates estimated from the Kaplan-Meier curves.
Note: Group-specific confidence intervals and the confidence interval for the differe
in single group.B (one each, AL group)), and one SAE (convulsions, AL
group) in Cohort 2. None of these SAEs were considered
related to study drug by investigators. Seven Cohort 2
subjects (5.6%) in the AZCQ group withdrew from treat-
ment due to an AE, versus one (0.8%) in the AL group.(Cohort 2)
PP population
26 AZCQ N = 114 AL N = 124
7.25, 100.00) 98.25 (95.39, 100.00) 100.00 (−,-)
-1.75 (−.-)
3.28, 100.00) 92.89 (87.69, 98.08) 97.56 (94.42, 100.00)
-4.67 (-10.6, 1.25)
5.91, 90.01) 70.56 (61.67, 79.45) 83.62 (76.65, 90.60)
-13.07 (-24.21, -1.92)
5.10, 81.52) 54.28 (44.57, 63.98) 73.90 (65.71, 82.08)
-19.62 (-32.16, -7.08)
4.00, 71.82) 47.04 (37.31, 56.77) 63.41 (54.49, 72.34)
-16.38 (-29.42, -3.33)
7.12, 65.46) 39.80 (30.24, 49.36) 56.74 (47.54, 65.94)
-16.94 (-30.04, -3.83)
AZCQ = azithromycin-chloroquine fixed-dose combination, CI = confidence
the standard error estimated by the Greenwood formula.
nce between treatment groups was not calculated when all failures occurred
Table 5 Descriptive summary of serum azithromycin and plasma chloroquine/desethylchloroquine concentrations
Study day Time post dose (hrs)
Mean (% CV) azithromycin serum concentrations*
Cohort 1 Cohort 2 Cohorts 1 and 2 combined
0 0 0 N = 52 0 N = 119 0 N = 171
2 0 216 (39) N = 49 195 (93) N = 114 201 (78) N = 163
2 3 1160 (44) N = 49 906 (58) N = 111 938 (54) N = 160
2 8 609 (48) N = 49 467 (59) N = 115 510 (56) N = 166
7 NS 44.7 (67) N = 48 26.9 (75) N = 118 320 (77) N = 166
Mean (% CV) chloroquine plasma concentrations*
0 0 0 N = 44 0 N = 107 0 N = 151
2 0 172 (35) N = 49 131 (53) N = 110 144 (48) N = 159
2 3 430 (36) N = 48 331 (44) N = 107 362 (43) N = 155
2 8 367 (43) N = 49 295 (40) N = 106 318 (43) N = 155
7 NS 54.5 (67) N = 49 35.1 (53) N = 112 41.0 (65) N = 166
Mean (% CV) desethylchloroquine plasma concentrations*
0 0 0 N = 43 0 N = 103 0 N = 146
2 0 95.1 (77) N = 49 77.5 (67) N = 110 82.9 (72) N = 159
2 3 170 (48) N = 49 138 (48) N = 107 148 (49) N = 156
2 8 160 (58) N = 49 147 (58) N = 104 151 (58) N = 153
7 NS 66.9 (94) N = 49 38.5 (87) N = 112 46.8 (97) N = 161
*Concentration is in ng/mL.
CV = coefficient of variation, NS = not specified.
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noted between AZCQ and AL treatment groups (See
Additional file 1).
The most frequently reported AEs in Cohort 2 overall
were asymptomatic parasitaemia (coded as infection
parasitic), vomiting, malaria, and pyrexia (Table 6). The
most frequently reported AEs in the AZCQ group were
vomiting (30.6%), asymptomatic parasitaemia (29.8%) and
malaria (21.0%). Those AEs most frequently reported and
considered related to AZCQ treatment were vomiting
(27.4%), asymptomatic parasitaemia (10.5%) and pruritus
(6.5%). Vomiting was a common reason for discontinu-
ation from dosing in the AZCQ group. Vomiting with
AZCQ generally resolved quickly (within the day of onset)
and appeared to be related to the AZCQ drug combin-
ation rather than an age-specific tolerability issue because
it was observed at a higher frequency in both cohorts. The
most frequently reported AEs in the AL group were
asymptomatic parasitaemia (23.7%), pyrexia (20.6%) and
malaria (14.5%), with pyrexia (10.7%), asymptomatic para-
sitaemia (10.7%) and vomiting (7.6%) considered related
to treatment. Most AEs across both treatment groups
were mild to moderate in severity.
Discussion
Based on the predefined primary endpoint in this
study, non-inferiority of AZCQ relative to AL was notdemonstrated. Although both treatment groups had a
high proportion of subjects achieving ACPR at Day 28
(PCR-corrected), the proportion was lower (i.e. inferior) in
the AZCQ group compared with the AL group.
In the PP population, the efficacy was 93% in AZCQ-
treated subjects compared with 99% in the AL-treated
subjects at Day 28. Similarly, in the MITT, efficacy was
89% in AZCQ-treated subjects compared with 98% in
AL-treated subjects. The conclusions from the sensitivity
analyses performed for all ACPR endpoints, including
subjects from the Ivory Coast and classifying study dis-
continuations as failures, were no different from the
main study conclusion. The evaluability criteria may ex-
plain the small difference in AZCQ efficacy observed be-
tween the PP and MITT populations, since subjects in
the PP population were required to receive all three days
of study medication. This study used the Kaplan-Meier
curve/product limit estimator to evaluate the primary
endpoint. Use of this limit estimator is recommended by
WHO [18] and has been used in analysing the primary
efficacy endpoint in late-stage anti-malarial treatment
clinical trials [19,20].
Absence of non-inferiority of AZCQ observed in this
study was an unexpected outcome because there is evi-
dence of effectiveness of AZ in combination with CQ and
other agents for treatment of malaria. In two randomized,
comparative studies in African adults with P. falciparum
Table 6 Treatment-emergent adverse events occurring
in ≥5% of subjects in Cohort 2 (all causalities)
System organ class preferred
term, n (%)
AZCQ N = 124 AL N = 131
Gastrointestinal disorders
Vomiting* 38 (30.6) 13 (9.9)
Abdominal pain† 4 (3.2) 14 (10.7)
Diarrhoea 4 (3.2) 8 (6.1)
Infections and infestations
Infection parasitic 37 (29.8) 31 (23.7)
Malaria 26 (21.0) 19 (14.5)
Upper respiratory tract infection 9 (7.3) 12 (9.2)
Bronchitis 4 (3.2) 9 (6.9)
Respiratory tract infection 2 (1.6) 8 (6.1)
General disorders and administration
site conditions
Pyrexia 17 (13.7) 27 (20.6)
Respiratory, thoracic and mediastinal
disorders
Cough 15 (12.1) 13 (9.9)
Metabolism and nutrition disorders
Decreased appetite 9 (7.3) 5 (3.8)
Nervous system disorders
Skin and subcutaneous tissue disorders
Pruritus 8 (6.5) 2 (1.5)
Medical Dictionary for Regulatory Activities (version 13.1) coding dictionary
applied.
*p < 0.0001 and †p < 0.05 using Fisher’s exact test.
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sulted in Day 28 PCR-corrected parasitologic clearance
rates of 98% [21]. In one study, AZ in combination with
artesunate was compared with AL in a population that in-
cluded children (≥eight years of age) and adults with un-
complicated P. falciparum malaria in Bangladesh [22].
Although the 42-day cure rate was numerically lower
(94.6%) for AZ-artesunate than for AL (97%), the differ-
ence was not statistically significant and at a level that was
therapeutically beneficial. This study was not powered for
equivalence. In another study, AZ was combined with
artesunate and compared with AL for treatment of un-
complicated P. falciparum malaria in children six to
59 months of age in Tanzania [23]. Treatment failures were
higher in the AZ-artesunate group, however, the dose of
AZ used was lower than in the current study (20 mg/kg
versus 30 mg/kg). In addition, CQ, alone and in combin-
ation with artesunate, AZ, or atovaquone-proguanil, has
been used to treat uncomplicated P. falciparum malaria in
similar-aged children in Malawi [24]. In this study, there
were no identified strains of CQ-resistant P. falciparum,
and the incidence of malaria was similar across the treat-
ment groups.In the present study, the serum AZ and plasma CQ con-
centrations were generally comparable between Cohorts 1
and 2. The large coefficient of variation may limit the abil-
ity to draw conclusions from these data. The mean values
of AZ, CQ, and desethyl-CQ concentrations at 0 hours on
Day 2 (prior to the third dose) and on Day 7 (after the
third dose) that were observed in this paediatric study
were similar to the concentrations at same PK sampling
time points observed in African adults treated with
1,000 mg AZ plus 600 mg CQ once daily for three days.
In the African study, the combination of AZ and CQ re-
sulted in an overall efficacy rate of 100% at Day 28 [7].
The overall proportion of subjects with AEs was similar
across treatment groups within each cohort, although
treatment-related AEs were reported more frequently in
the AZCQ group in both cohorts. Posthoc analysis of the
frequency of AEs in cohort 2 showed that, for most, there
was no statistically significant difference between treat-
ment groups, however, vomiting was more frequent in the
AZCQ group and abdominal pain was more frequent in
the AL group. Study discontinuation due to AEs was
higher in the AZCQ group in Cohort 2. No unexpected
safety signals were identified beyond the known AE profile
of individually dosed AZ or CQ.
In this study, efficacy of AZCQ was inferior to AL.
Therefore, consideration of future use of AZCQ for IPT
or seasonal malaria chemoprophylaxis may require add-
itional study to determine whether a combination of AZ
with other malaria drug(s) or use of an alternative dosing
regimen with higher AZ dosing improves response to
treatment with AZCQ in children aged six to 59 months.
Additional file
Additional file 1: Median change from baseline to last observation*
in laboratory values in cohort 2.
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